HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily

According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To date,...

Descripción completa

Detalles Bibliográficos
Autores principales: IENI, A., BARRESI, V., GIUFFRÈ, G., CARUSO, R.A., LANZAFAME, S., VILLARI, L., SALOMONE, E., ROZ, E., CABIBI, D., FRANCO, V., CERTO, G., LABATE, A., NAGAR, C., MAGLIOLO, E., BROGGI, B., FAZZARI, C., ITALIA, F., TUCCARI, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833944/
https://www.ncbi.nlm.nih.gov/pubmed/24260051
http://dx.doi.org/10.3892/ol.2013.1611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833944/
https://www.ncbi.nlm.nih.gov/pubmed/24260051
http://dx.doi.org/10.3892/ol.2013.1611

Ejemplares similares